Kythera (Acquired by Allergan)
Press releases archived for reference only.
30930 Russell Ranch Road
Westlake Village
California
91362
United States
Tel: 818-587-4500
Fax: 818-587-4591
Website: http://www.kythera.com/
About Kythera (Acquired by Allergan)
Oct. 1, 2015 -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that it has successfully completed the acquisition of Kythera Biopharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel prescription products for the medical aesthetics market. Allergan acquired Kythera in an all-cash transaction valued at approximately $2.1 billion.
121 articles about Kythera (Acquired by Allergan)
-
Sienna Biopharma Launches with $34 Million and a Roster Full of Former Kythera Execs
5/2/2016
-
Allergan's Kythera to Slash 117 Jobs After Merger is Completed
10/16/2015
-
Allergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment For Double-Chin
10/1/2015
-
Allergan And Kythera Announce That Pending Transaction Will Now Be For All-Cash Consideration
8/5/2015
-
Allergan And Kythera Announce Early Termination Of Hart-Scott-Rodino Waiting Period For Allergan's Pending Acquisition Of KYTHERA
7/28/2015
-
Allergan Coughs Up $2.1 Billion for Double-Chin Drugmaker Kythera
6/18/2015
-
Kythera Grants Stock Options Under Inducement Program
6/17/2015
-
Kythera To Present At The Bank of America Merrill Lynch 2015 Health Care Conference
5/11/2015
-
Kythera Releases First Quarter 2015 Operating Results And Progress Update
5/8/2015
-
Kythera Grants Stock Options Under Inducement Program
5/7/2015
-
Kythera Grabs FDA Approval for Chin Fat-Busting Drug
5/4/2015
-
Kythera To Release First Quarter 2015 Operating Results
5/1/2015
-
Kythera Announces FDA Approval Of KYBELLA (Also Known As ATX-101)
4/30/2015
-
Kythera Grants Stock Options Under Inducement Program
4/6/2015
-
Kythera Announces 2015 Outlook Call
3/20/2015
-
Kythera Announces Closing Of Public Offering And Exercise Of Underwriters' Over-Allotment Option
3/17/2015
-
Kythera Announces Pricing Of Public Offering Of Common Stock
3/11/2015
-
Kythera Announces Proposed Public Offering Of Common Stock
3/10/2015
-
Kythera Announces FDA Advisory Committee Unanimously (17-0) Recommends To Approve ATX-101 (Deoxycholic Acid) Injection To Improve The Appearance Of Moderate To Severe Submental Fullness
3/10/2015
-
Stock Jumps as FDA Staff Backs Kythera's Double Chin Injection
3/9/2015